Organic Active Ingredients TRIZ Cases

Sugar and polymer excipients help lyophilized cells retain viability without ultra-low-temperature shipping.

This case uses heat-triggered retro-Diels-Alder linkers on nanoparticles to improve the timing and location of therapeutic release.

Ionizable, PEG-containing lipid nanoparticles target stem cell markers, offering a simpler nonviral route for therapeutic RNA delivery.

This case uses counter-ion exchange and crystallization to simplify production of high-purity nicotinamide ribofuranoside salts.

Inositol derivatives block AhR signaling to suppress ROS and cancer cell growth.

Fluorescent probes localize ergosterol peroxide derivatives and reveal targets linked to ROS-driven apoptosis in TNBC cells.

A fixed-dose nefazodone and risperidone combination simplifies treatment while targeting suicide ideation and impulsivity.

This case replaces limited single-biomarker screening with a 14-gene score for detection, progression, surgery, and therapy response.

Enteric polymer salts stabilize ASD release across buffer capacities while supporting higher drug loading.

This gout case uses cyclodextrin-conjugated polymers to remove uric acid crystals while supporting targeted delivery and drug imaging.

Fluorinated polyketides bind tubulin and disrupt microtubule dynamics, supporting stronger antitumor activity with less systemic toxicity.

This case uses inhaled, nasal, or sublingual 5-MeO-DMT regimens to address psychomotor retardation and support compliance.

Compound (1) mediates stable cancer-agent delivery, including across the blood-brain barrier.

This case combines psilocin and psilocybin in a co-crystal to support rapid absorption, stability, and reduced cardiac risks.

This PF-ILD case combines Nintedanib with a PDE4B inhibitor to suppress fibroblast activation and proliferation with improved tolerability.

Pouched oral compositions use substituted pyridine analogs for rapid, complete mucosal absorption and reduced consumption.

The process combines water, olive or hemp seed oil, kneading, filtration, and separation to produce concentrated oils with low THC.

Soluble ActRII polypeptides block GDF/BMP signaling to reduce pulmonary pressure, vascular remodeling, and right ventricular hypertrophy.

Swelling, lysis, and sealing load dexamethasone into erythrocytes for prolonged symptom control with reduced systemic effects.

Anatabine glutarate crystals target NFKB and STAT3 pathways to reduce inflammation.

This case examines Formula (I) compounds designed to inhibit viral replication across coronaviruses, picornaviruses, and noroviruses.

This case addresses side effects and drug resistance with CRBN ligands that recruit E3 ligase activity for targeted protein degradation.

This case uses citron kinase inhibitors to address androgen-independent prostate cancer and expand treatment options.

Fixed-dose D-DHA with periodic blood-ratio analysis helps clinicians adjust treatment for DHA intake and compliance variability.

Formula I sGC stimulators work with nitric oxide to raise cGMP and modulate downstream effectors across disease contexts.

Specific R1, R2, and R3 substituents tune indazole structures for TRIB2 and YAP inhibition across oral, topical, and parenteral therapies.

This case uses oral Compound I to target cardiac myosin directly, improving ejection fraction without affecting calcium homeostasis.

Quinolinone MAT2A inhibitors block SAM synthesis, targeting MTAP-deficient cancer cells and reducing harm to normal tissues.

Synthetic polynucleotide vehicles use recognition sequences to target cancer cells, enabling cargo uptake and genomic integration.

This case uses GHB-related JON-11 analogues and pro-moieties to improve CaMK2a targeting, stability, and brain entry.

Forms I–III use controlled crystallization to support purification, storage stability, and bioavailability of Compound A.

Tris, sucrose, sodium citrate, and surfactants help stabilize rAAV through lyophilization, storage, and freeze-thaw cycles.

Targeting Polθ with heterocyclic derivatives disrupts MMEJ repair and may restore sensitivity to cisplatin and PARPi.

This case uses small-molecule ACSS2 inhibitors to disrupt acetate metabolism and address treatment resistance in brain metastases.

Once-daily 1.25% pilocarpine supports presbyopia vision with fewer ocular side effects.

This case uses ASOs to exclude decay-inducing SCN1A exons, increasing functional NaV1.1 protein for Dravet Syndrome.

A non-aqueous solvent helps preserve triazole activity, reduce drug loss, and extend local retention in topical eye and ear treatment.

This case uses cyclophosphamide-resistant ALDH1 stem cells with non-myeloablative dosing to preserve immunity and shorten recovery.

This case uses pyrimidine derivatives to inhibit TGF-β signaling, preserve pulmonary function, and alleviate pneumoconiosis symptoms.

A tetraheterocyclic compound targets G12D, G12V, G12C, G13D, and Q61H KRAS mutations for cancer treatment.

Explore quinazoline compounds that selectively inhibit PI3K isoforms, improving cancer-cell suppression while addressing safety concerns.

This case uses a heterocyclic compound with varied substituents to improve orexin type 2 efficacy, safety, and pharmacokinetic performance.

This case uses modified 2H-benzotriazole structures to balance ejaculation control, bioavailability, and dose-related side effects.

Explore heterocyclic kinase analogs that tune substituents to preserve ABL, SRC, and LCK activity against resistant mutants.

Novel benzopyran compounds combine enzyme targeting, apoptosis, and DNA damage to counter resistance and limit tumor cell proliferation.

This case shows how 06-Methyl-dGTP bypasses MGMT-linked resistance while blocking tumor growth and cell-cycle progression.

Specific lipid structures help nucleic acids reach target cells and organs while preserving biological activity in vivo.

This case uses modular carbonyl-fused heterocyclic structures to improve USP1 inhibition in tumors with DNA repair deficiencies.

Rosemary extract, eugenol, vitamin E, or lecithin help preserve THC at room temperature without heating.

Solvent control, seed crystals, XRD, and thermal analysis identify a stable pyrazolopyrimidine crystal with low residual solvents.